Drug intelligence / Profile preview

LYB014

Development stage: Phase 1
Lead developer: Yantai Patronus Biotech
Modality: Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

**LYB014** is an investigational recombinant protein malaria vaccine from Patronus Biotech that uses the proprietary U-VLP® virus-like-particle platform. It is designed to induce protective humoral and cellular immune responses against *Plasmodium falciparum* across multiple parasite life-cycle stages, with the program described as targeting all three critical stages of the parasite life cycle. The candidate is being evaluated with the low-cost A02 adjuvant system and remains in preclinical/IND-enabling development for malaria prevention. ([prnewswire.com](https://www.prnewswire.com/apac/news-releases/patronus-biotech-receives-grant-to-evaluate-a-novel-malaria-vaccine-and-adjuvant-to-support-affordable-access-and-use-in-global-health-302626605.html))

Other names: Malaria Vaccine疟疾疫苗

Beyond the preview

Go deeper on LYB014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYB014.